Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China
Retrospective analysis shows ixazomib improves progression-free survival in transplant-ineligible multiple myeloma patients, indicating it as a strong first-line treatment.
Key Points
This study evaluates the efficacy and safety of ixazomib-based regimens in treating newly diagnosed multiple myeloma patients.
Retrospective database analysis of patients in the NICHE-MM registry
Included transplant-ineligible patients aged 18 and older
Primary outcomes include overall survival, progression-free survival, and treatment patterns
Overall response rate of 82%, with 32% achieving complete response
Median progression-free survival of 24.2 months observed